Entera Bio Ltd. - Ordinary Shares (NQ:ENTX)

2.860 -0.060 (-2.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Entera Bio Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >

121 Stocks That Hit Their 52-Week Low ↗

October 14, 2022

New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.

Via Benzinga

Entera Bio: Q2 Earnings Insights ↗

August 11, 2022

Entera Bio (NASDAQ:ENTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO ↗

July 18, 2022

Via Benzinga

Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket ↗

October 10, 2022

Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,...

Via Benzinga

$5.1 Million Bet On Tabula Rasa HealthCare? 3 Penny Stocks Insiders Are Buying ↗

July 26, 2022

US crude oil futures traded higher by around 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary ↗

July 18, 2022

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...

Via Benzinga

Recap: Entera Bio Q1 Earnings ↗

May 12, 2022

Entera Bio (NASDAQ:ENTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Entera Bio Q4 Earnings ↗

March 08, 2022

Entera Bio (NASDAQ:ENTX) reported its Q4 earnings results on Tuesday, March 8, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022 ↗

September 06, 2022

Upgrades

Via Benzinga

41 Stocks Moving In Tuesday's Mid-Day Session ↗

June 14, 2022

Gainers Revlon, Inc. (NYSE: REV) rose 125.5% to $2.6499. Revlon’s stock dropped sharply on Monday after the company is reportedly expected to file for bankruptcy.

Via Benzinga

This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday ↗

July 22, 2022

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period...

Via Benzinga

Follow the Insiders and Buy the Dip in These 3 Stocks ↗

May 06, 2022

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

Via InvestorPlace

82 Biggest Movers From Yesterday ↗

June 15, 2022

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.

Via Benzinga

Recession Fears are Creating a Golden Opportunity for Biotech Stocks ↗

April 08, 2022

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.

Via InvestorPlace

4 Penny Stocks Insiders Are Buying: Crexendo, Performant Financial And More ↗

January 20, 2022

Silver prices surged above $24 per troy ounce for the first time in more than two months and investors also focused on some notable insider...

Via Benzinga

5 Penny Stocks Insiders Are Buying ↗

January 19, 2022

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste...

Via Benzinga

Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data ↗

October 06, 2021

Entera Bio Ltd (NASDAQ: ENTX) has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid...

Via Benzinga

Neurodegenerative Disease And Cancer Stocks Among Top Biotech Gainers In 2021 ↗

July 04, 2021

Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF IBB advancing about 8% year-to-date compared to the roughly 14% gain for the S&P...

Via Talk Markets

Topics Stocks

Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021 ↗

July 04, 2021

Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) advancing about 8% year-to-date ...

Via Benzinga

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO ↗

October 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

45 Biggest Movers From Yesterday ↗

June 24, 2021

Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613. First...

Via Benzinga

Earnings Scheduled For August 16, 2021 ↗

August 16, 2021

Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to...

Via Benzinga

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗

June 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Where Might Entera Bio Stock End Up After Rallying Wednesday ↗

June 23, 2021

Entera Bio Ltd (NASDAQ: ENTX) shares rallied higher Wednesday after the company announced it saw positive results from its final six-month bone mineral density results from...

Via Benzinga

ENTX Stock: The Huge FDA News Sending Entera Bio Soaring ↗

June 23, 2021

Today, investors in ENTX stock are seeing gains of approximately 40% as the company announced results from one of its clinical trials.

Via InvestorPlace

Mid-Afternoon Market Update: Patterson Companies Drops On Earnings Miss; Entera Bio Shares Gain ↗

June 23, 2021

Toward the end of trading Wednesday, the Dow traded down 0.08% to 33,918.98 while the NASDAQ rose 0.16% to 14,276.41. The S&P also rose, gaining 0.05% to 4,248.47. The U.S....

Via Benzinga

Topics Stocks

Nasdaq Notches Intraday High, SPX Eyes Third-Straight Win ↗

June 23, 2021

The Dow Jones Industrial Average is modestly lower this afternoon, walking back this morning's gains to register a 19-point drop.

Via Talk Markets

Topics Stocks

Why Entera Bio, Orphazyme, Bellerophon Are Moving Today ↗

June 23, 2021

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday. Entera Bio Climbs...

Via Benzinga

Why Entera Bio Shares Are Skyrocketing Today ↗

June 23, 2021

Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher by 47.66% at $6.63 Wednesday after the company announced the topline Phase 2 clinical trial of EB613 met its primary...

Via Benzinga

Mid-Day Market Update: Crude Oil Rises Over 1%; Gemini Therapeutics Shares Slide ↗

June 23, 2021

Midway through trading Wednesday, the Dow traded up 0.01% to 33,948.64 while the NASDAQ rose 0.19% to 14,280.41. The S&P also rose, gaining 0.10% to 4,250.86. The U.S. has the...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.